Details for Patent: 12,168,666

Which drugs does patent 12,168,666 protect, and when does it expire?

Patent 12,168,666 protects COSELA and is included in one NDA.

This patent has six patent family members in four countries.

Summary for Patent: 12,168,666

Title:	Morphic forms of trilaciclib and methods of manufacture thereof
Abstract:	An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
Inventor(s):	Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
Assignee:	Ardena Holding NV , Pharmacosmos Holding AS , Pharmacosmos AS
Application Number:	US17/236,687
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,168,666
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 12,168,666

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacosmos	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes	12,168,666		Y	Y

International Family Members for US Patent 12,168,666

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
China	116157403
China	120398896
European Patent Office	4164653